Abstract: According to one aspect, a vehicle includes hardware systems configured to support the autonomous or semi-autonomous operation of the vehicle. Hardware systems may include a main compute, a brain stem computer (BSC), and an aggregator/compute arrangement or redundant autonomy compute. Such hardware systems may cooperate to allow the vehicle to operate autonomously, and typically provide capabilities, e.g., redundant and/or backup capabilities, configured to enable the vehicle to continue to operate in the event that a primary system is not functioning as expected. The aggregator/compute arrangement may further be comprised of two substantially identical modules or computing assemblies, each configured to process sensor data and perform backup autonomy functionalities and/or teleoperations functionalities.

Abstract: According to one aspect, a vehicle includes hardware systems configured to support the autonomous or semi-autonomous operation of the vehicle. Hardware systems may include a main compute, a brain stem computer (BSC), and an aggregator/compute arrangement or redundant autonomy compute. Such hardware systems may cooperate to allow the vehicle to operate autonomously, and typically provide capabilities, e.g., redundant and/or backup capabilities, configured to enable the vehicle to continue to operate in the event that a primary system is not functioning as expected. The aggregator/compute arrangement may further be comprised of two substantially identical modules or computing assemblies, each configured to process sensor data and perform backup autonomy functionalities and/or teleoperations functionalities.

Abstract: A quick release axle slider to be used with a motorcycle may include a slider base; a first magnetic ring to cooperate with the slider base; a rod to connect to the first magnetic ring; and a first fastener to extend through the slider base through the first magnetic ring and to connect to the rod.

Abstract: The present invention is based on the discovery of associations that exist between single nucleotide polymorphisms (SNPs) on chromosome 19 and virological outcomes in a diverse population of patients with hepatitis C virus (HCV) who received interferon-free treatment.

Abstract: The present invention is based on the discovery of associations that exist between single nucleotide polymorphisms (SNPs) on chromosome 4 and virological outcomes in a diverse population of patients with hepatitis C virus (HCV) who received interferon-based treatment.

Abstract: The present invention is based on the discovery of associations that exist between single nucleotide polymorphisms (SNPs) on chromosome 19 and virological outcomes in a diverse population of patients with hepatitis C virus (HCV) who received interferon-based treatment.

Abstract: A device to protect the frame of the motorcycle may include An engine to drive the motorcycle, a frame to support the motorcycle, a left bracket to mount on a left side of the motorcycle between the frame and engine, and a right bracket to mount on the right side of the motorcycle between the frame and engine. The left bracket may be connected to a first frame slider, and the right bracket may be connected to a second frame slider. The first frame slider may extend beyond the frame of the motorcycle, and the second frame slider may extend beyond the frame of the motorcycle. The left bracket may include a first portion and the left bracket may include a second portion connected to the first portion. The left bracket may include a third portion connected to the second portion and the third portion may include a first side wall, a second side wall and a top wall to connect to the frame.

Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.